Sydney Jennings

2 weeks ago | patientcareonline.com | Foluso Fakorede |Sydney Jennings

Peripheral artery disease (PAD) remains one of the most prevalent and debilitating cardiovascular conditions, yet awareness of PAD remains low among clinicians, including primary care physicians. In this conversation at ACP Internal Medicine Meeting 2025, Foluso Fakorede, MD emphasizes the crucial need for greater awareness of PAD, detailing its risk factors, prevalence, and the importance of screening, especially among high-risk populations.

2 weeks ago | patientcareonline.com | Sydney Jennings

Regeneron Pharmaceuticals, in partnership with Sanofi, will unveil new clinical findings for dupilumab (Dupixent®) at the upcoming American Thoracic Society (ATS) International Conference 2025, being held May 18-21 in San Francisco, California.1,2 The data, including late-breaking posters and an oral presentation, highlights the benefits of dupilumab in treating chronic respiratory diseases driven by type 2 inflammation, such as chronic obstructive pulmonary disease (COPD) and asthma.1,2 The...

2 weeks ago | patientcareonline.com | Sydney Jennings

May 1, 2025Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen. On April 1, 2025, we reported on late-breaking data from the randomized, double-blind, placebo-controlled EKSTROM trial presented at the American College of Cardiology 74th Annual Scientific Session and Expo.

2 weeks ago | patientcareonline.com | Sydney Jennings

Higher levels of perceived stress were significantly associated with worse respiratory health status and elevated biomarkers of platelet activation and oxidative stress in former smokers with chronic obstructive pulmonary disease (COPD), according to a new study.1“There is increased evidence that psychosocial factors, including perceived stress, are associated with worsened respiratory symptoms for people with COPD.

2 weeks ago | patientcareonline.com | Sydney Jennings

A collaborative research initiative between Boehringer Ingelheim, the University of Oxford, and Cumulus Neuroscience has launched a first-of-its-kind study to objectively measure brain activity, mood, and behavior in individuals diagnosed with borderline personality disorder (BPD). The study will use wearable electroencephalogram (EEG) technology and digital cognitive assessments to collect real-world, high-frequency data from participants in both clinical and home settings.